The Problem at the Heart of Public Access
The intended beneficiary of public access is “the American public,” and we need so much more than access to the biomedical literature.
The intended beneficiary of public access is “the American public,” and we need so much more than access to the biomedical literature.
A lurid story of intramural hijinks at the FDA shows how far from mission an organization can drift when it gets its priorities wrong.
Registering clinical trials after enrollment has commenced may lead to the perception that medical researchers are peeking.